Author

L. Vazquez

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 1 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Research Focus:host-pathogen & immune response· 2 Organism:human· 1 Organism:mouse· 1

Frequent Co-Authors

C. Q. Sacramento· 2 shared H. C. Castro-Faria-Neto· 2 shared J. R. Temerozo· 2 shared N. Fintelman-Rodrigues· 2 shared O. A. Chaves· 2 shared P. T. Bozza· 2 shared R. Q. Monteiro· 2 shared T. M. L. Souza· 2 shared

Activity by Year

2021-2021 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersPharmacology & Toxicology

C. Q. Sacramento

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Atazanavir is a competitive inhibitor of SARS-CoV-2 Mpro, impairing variants replication in vitro and in vivo

O. A. Chaves, C. Q. Sacramento, A. C. Ferreira, M. Mattos, N. Fintelman-Rodrigues, J. R. Temerozo, D. P. Pinto, G. P. E. da Silveira, L. B. da Fonseca, H. M. Pereira, A. S. Carlos, J. d. C. P. d'Avila, J. P. B. Viola, R. Q. Monteiro, L. Vazquez, , T. M. L. Souza

This study shows that atazanavir inhibits SARS-CoV-2 Mpro, effectively reducing replication of both B.1 and gamma variants in vitro and in vivo.

bioRxiv · Nov 24, 2021Pharmacology & Toxicology

Apixaban, an orally available anticoagulant, inhibits SARS-CoV-2 replication by targeting its major protease in a non-competitive way

O. A. Chaves, C. Q. Sacramento, N. Fintelman-Rodrigues, J. R. Temerozo, F. Pereira-Dutra, D. M. Mizurini, R. Q. Monteiro, L. Vazquez, P. T. Bozza, H. C. Castro-Faria-Neto, T. M. L. Souza

This study shows apixaban inhibits SARS-CoV-2 replication by targeting its Mpro protease non-competitively, with higher potency than boceprevir.

bioRxiv · Sep 23, 2021 · PreprintMicrobiology